Comment on

• HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement.

  Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Jacobs TW, et al. Am J Clin Pathol. 2000 Feb;113(2):251-8. doi: 10.1309/980M-E24R-V19K-595D. Am J Clin Pathol. 2000. PMID: 10664627
• Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry.

  O'Malley FP, Parkes R, Latta E, Tjan S, Zadro T, Mueller R, Arneson N, Blackstein M, Andrulis I. O'Malley FP, et al. Am J Clin Pathol. 2001 Apr;115(4):504-11. doi: 10.1309/VP4W-5C55-7M09-6TX3. Am J Clin Pathol. 2001. PMID: 11293897
• Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis.

  Lehr HA, Jacobs TW, Yaziji H, Schnitt SJ, Gown AM. Lehr HA, et al. Am J Clin Pathol. 2001 Jun;115(6):814-22. doi: 10.1309/AJ84-50AK-1X1B-1Q4C. Am J Clin Pathol. 2001. PMID: 11392876
• Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard.

  Wang S, Saboorian MH, Frenkel EP, Haley BB, Siddiqui MT, Gokaslan S, Wians FH Jr, Hynan L, Ashfaq R. Wang S, et al. Am J Clin Pathol. 2001 Oct;116(4):495-503. doi: 10.1309/TMUW-G4WB-LXJ2-FUDN. Am J Clin Pathol. 2001. PMID: 11601134